In: In vivo CAR-T

ESO-T01

AstraZeneca · Pregene Biopharma

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Early Phase 1 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo BCMA CAR-T, lentiviral
How it’s given
“ESO-T01 injection is the third-generation self-inactivating lentiviral vector targeting T cells in vivo, which carries a single VHH-directed BCMA-targeted CAR.”In the company’s words, NCT06791681 on ClinicalTrials.gov
Tested for
Relapsed/ Refractory Multiple Myeloma
Main trialEarly Phase 1
“This is a single center, single arm, open-label, dose-escalation clinical study to observe the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics of ESO-T01 injection for treating patients with relapsed/refractory multiple myeloma.”In the company’s words, NCT06791681 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Early Phase 1Recruiting 30 Nov 2027 A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Early Phase 1Suspended 1 Nov 2027 A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026

Follow ESO-T01

Following is part of Solo: you see every change to ESO-T01 the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in